PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 12, 2005, Pages 1463-1465

  Ishii, Kazunari ^a   Minoshima, Satoshi ^b   Pupi, Alberto ^c,e   Nobili, Flavio Mariano ^d  

^a Hyogo Brain and Heart Center at Himeji   (Japan)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; FLUORODEOXYGLUCOSE F 18; OXYGEN 15; WATER;

ALZHEIMER DISEASE; BRAIN MAPPING; BRAIN REGION; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; EARLY DIAGNOSIS; FRONTAL CORTEX; FUNCTIONAL ASSESSMENT; GENOTYPE; HIPPOCAMPUS; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; NEUROIMAGING; NEUROLOGIC EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; REVIEW; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY;

EID: 28544442225     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1936-3     Document Type: Review

References (30)

1. 1. S Minoshima B Giordani S Berent KA Frey NL Foster DE Kuhl 1997 Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease Ann Neurol 42 85 94 10.1002/ana.410420114 9225689 Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94
2. 2. DH Silverman 2004 Brain 18 F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging J Nucl Med 45 594 607 15073255 Silverman DH. Brain 18 F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594–607
3. 3. L Mosconi 2005 Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD Eur J Nucl Med Mol Imaging 32 486 510 10.1007/s00259-005-1762-7 15747152 Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486–510
4. 4. G Chetelat B Desgranges V Sayette de la F Viader F Eustache JC Baron 2003 Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 60 1374 1377 12707450 Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 2003;60:1374–7
5. 5. A Drzezga N Lautenschlager H Siebner M Riemenschneider F Willoch S Minoshima 2003 Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study Eur J Nucl Med Mol Imaging 30 1104 1113 10.1007/s00259-003-1194-1 12764551 Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104–13
6. 6. L Mosconi D Perani S Sorbi K Herholz B Nacmias V Holthoff 2004 MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET Neurology 63 2332 2340 15623696 Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332–40
7. 7. C Huang LO Wahlund L Svensson B Winblad P Julin 2002 Cingulate cortex hypoperfusion predicts Alzheimer’s disease in mild cognitive impairment BMC Neurol 2 9 10.1186/1471-2377-2-9 12227833 Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex hypoperfusion predicts Alzheimer’s disease in mild cognitive impairment. BMC Neurol 2002;2:9
8. 8. M Encinas R Juan De A Marcos P Gil A Barabash C Fernandez 2003 Regional cerebral blood flow assessed with 99m Tc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer’s disease Eur J Nucl Med Mol Imaging 30 1473 1480 10.1007/s00259-003-1277-z 14579086 Encinas M, De Juan R, Marcos A, Gil P, Barabash A, Fernandez C, et al. Regional cerebral blood flow assessed with 99m Tc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2003;30:1473–80
9. 9. H Fukuyama M Ogawa H Yamauchi S Yamaguchi J Kimura Y Yonekura 1994 Altered cerebral energy metabolism in Alzheimer’s disease: a PET study J Nucl Med 35 1 6 8271029 Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, et al. Altered cerebral energy metabolism in Alzheimer’s disease: a PET study. J Nucl Med 1994;35:1–6
10. 10. R Mielke K Herholz M Grond J Kessler WD Heiss 1992 Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type Neurobiol Aging 13 1 93 98 10.1016/0197-4580(92)90015-P 1542386 Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging 1992;13(1): 93–8
11. 11. F Yasuno T Imamura N Hirono K Ishii M Sasaki Y Ikejiri 1998 Age at onset and regional cerebral glucose metabolism in Alzheimer’s disease Dement Geriatr Cogn Disord 9 63 67 10.1159/000017024 9524795 Yasuno F, Imamura T, Hirono N, Ishii K, Sasaki M, Ikejiri Y, et al. Age at onset and regional cerebral glucose metabolism in Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:63–7
12. 12. S Sakamoto K Ishii M Sasaki K Hosaka T Mori M Matsui 2002 Differences in cerebral metabolic impairment between early and late onset types of Alzheimer’s disease J Neurol Sci 200 27 32 10.1016/S0022-510X(02)00114-4 12127672 Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, et al. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer’s disease. J Neurol Sci 2002;200:27–32
13. 13. A Drzezga M Riemenschneider B Strassner T Grimmer M Peller A Knoll 2005 Cerebral glucose metabolism in patients with AD and different APOE genotypes Neurology 64 102 107 15642911 Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, et al. Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 2005;64:102–7
14. 14. L Mosconi K Herholz I Prohovnik B Nacmias MT Cristofaro De M Fayyaz 2005 Metabolic interaction between ApoE genotype and onset age in Alzheimer’s disease: implications for brain reserve J Neurol Neurosurg Psychiatry 76 15 23 10.1136/jnnp.2003.030882 15607989 Mosconi L, Herholz K, Prohovnik I, Nacmias B, De Cristofaro MT, Fayyaz M, et al. Metabolic interaction between ApoE genotype and onset age in Alzheimer’s disease: implications for brain reserve. J Neurol Neurosurg Psychiatry 2005;76:15–23
15. 15. EM Reiman RJ Caselli LS Yun K Chen D Bandy S Minoshima 1996 Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E N Engl J Med 334 752 758 10.1056/NEJM199603213341202 8592548 Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752–8
16. 16. GW Small LM Ercoli DH Silverman SC Huang S Komo SY Bookheimer 2000 Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease Proc Natl Acad Sci U S A 97 6037 6042 10.1073/pnas.090106797 10811879 Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A 2000;97:6037–42
17. 17. WJ Powers JS Perlmutter TO Videen P Herscovitch LK Griffeth HD Royal 1992 Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer’s disease Neurology 42 765 770 1565229 Powers WJ, Perlmutter JS, Videen TO, Herscovitch P, Griffeth LK, Royal HD, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer’s disease. Neurology 1992;42:765–70
18. 18. K Ishii M Sasaki S Yamaji S Sakamoto H Kitagaki E Mori 1997 Decreased posterior cingulate perfusion in mild Alzheimer’s disease shown by H 2 15 O-PET Eur J Nucl Med 24 670 673 9169576 Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Decreased posterior cingulate perfusion in mild Alzheimer’s disease shown by H 2 15 O-PET. Eur J Nucl Med 1997;24:670–3
19. 19. K Ishii M Sasaki M Matsui S Sakamoto S Yamaji N Hayashi 2000 A diagnostic method for suspected Alzheimer’s disease using H 2 15 O positron emission tomography perfusion Z score Neuroradiology 42 787 794 10.1007/s002340000404 11151682 Ishii K, Sasaki M, Matsui M, Sakamoto S, Yamaji S, Hayashi N, et al. A diagnostic method for suspected Alzheimer’s disease using H 2 15 O positron emission tomography perfusion Z score. Neuroradiology 2000;42:787–94
20. 20. N Scarmeas C Habeck KE Anderson J Hilton DP Devanand GH Pelton 2004 Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele) Am J Geriatr Psychiatry 12 596 605 10.1176/appi.ajgp.12.6.596 15545327 Scarmeas N, Habeck C, Anderson KE, Hilton J, Devanand DP, Pelton GH, et al. Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele). Am J Geriatr Psychiatry 2004;12:596–605
21. 21. N Scarmeas KE Anderson J Hilton A Park C Habeck J Flynn 2004 APOE-dependent PET patterns of brain activation in Alzheimer disease Neurology 63 913 915 15365149 Scarmeas N, Anderson KE, Hilton J, Park A, Habeck C, Flynn J, et al. APOE-dependent PET patterns of brain activation in Alzheimer disease. Neurology 2004;63:913–5
22. 22. R Mielke U Pietrzyk A Jacobs GR Fink A Ichimiya J Kessler 1994 HMPAO SPET and FDG PET in Alzheimer’s disease and vascular dementia: comparison of perfusion and metabolic pattern Eur J Nucl Med 21 1052 1060 10.1007/BF00181059 7828614 Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, et al. HMPAO SPET and FDG PET in Alzheimer’s disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med 1994;21:1052–60
23. 23. C Messa D Perani G Lucignani A Zenorini F Zito G Rizzo 1994 High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer’s disease: comparison with fluorine-18-FDG PET J Nucl Med 35 210 216 8294987 Messa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer’s disease: comparison with fluorine-18-FDG PET. J Nucl Med 1994;35:210–6
24. 24. K Ishii M Sasaki S Sakamoto S Yamaji H Kitagaki E Mori 1999 Tc-99m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy-d-glucose PET in Alzheimer’s disease. Comparison of perfusion and metabolic patterns Clin Nucl Med 24 572 575 10.1097/00003072-199908000-00005 10439176 Ishii K, Sasaki M, Sakamoto S, Yamaji S, Kitagaki H, Mori E. Tc-99m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy-d-glucose PET in Alzheimer’s disease. Comparison of perfusion and metabolic patterns. Clin Nucl Med 1999;24:572–5
25. 25. K Herholz H Schopphoff M Schmidt R Mielke W Eschner K Scheidhauer 2002 Direct comparison of spatially normalized PET and SPECT scans in Alzheimer’s disease J Nucl Med 43 21 26 11801698 Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer’s disease. J Nucl Med 2002;43:21–6
26. 26. N Dobert J Pantel L Frolich N Hamscho C Menzel F Grunwald 2005 Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index Dement Geriatr Cogn Disord 20 63 70 10.1159/000085857 15908747 Dobert N, Pantel J, Frolich L, Hamscho N, Menzel C, Grunwald F. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index. Dement Geriatr Cogn Disord 2005;20:63–70
27. 27. K Ishii F Willoch S Minoshima A Drzezga EP Ficaro DJ Cross 2001 Statistical brain mapping of 18 F-FDG PET in Alzheimer’s disease: validation of anatomic standardization for atrophied brains J Nucl Med 42 548 557 11337540 Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al (2001) Statistical brain mapping of 18 F-FDG PET in Alzheimer’s disease: validation of anatomic standardization for atrophied brains. J Nucl Med 2001;42:548–57
28. 28. JH Burdette S Minoshima T Borght Vander DD Tran DE Kuhl 1996 Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections Radiology 198 837 843 8628880 Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology 1996;198:837–43
29. 29. K Herholz E Salmon D Perani JC Baron V Holthoff L Frolich 2002 Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET NeuroImage 17 302 316 10.1006/nimg.2002.1208 12482085 Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage 2002;17:302–16
30. 30. E Imabayashi H Matsuda T Asada T Ohnishi S Sakamoto S Nakano 2004 Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer’s disease from controls using brain perfusion SPECT J Nucl Med 45 1450 1457 15347711 Imabayashi E, Matsuda H, Asada T, Ohnishi T, Sakamoto S, Nakano S. Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer’s disease from controls using brain perfusion SPECT. J Nucl Med 2004;45:1450–7